Table 2 Clinical and serological characteristics of included patients (nominal variables)
Nominal variables | n | Absolute frequency | ||
|---|---|---|---|---|
Gender (f/m) | 17 | 10 (53.3%)/7 (47.7%) | ||
Body Mass Index (BMI) scoring*1 | 17 | 3 (17.7%)/3 (17.7) /11 (64.7%)/0 (0%) | ||
Severe under-/under-/normal-/overweight | ||||
Pancreatic insufficiency | 17 | 13 (76.5%) | ||
Diabetes mellitus | 17 | 6 (35%) | ||
Allergy | 17 | 10 (59.0%) | ||
Chronic rhinosinusitis (CRS) | 17 | 11 (65%) | ||
EPOS criteria for CRS at inclusion [28]: | No | Acute remittent | Chronic | |
Nasal blockage or obstruction or congestion | 3 (17.6%) | 2 (11.8%) | 12 (70.6%) | |
Anterior or posterior nasal drip | 2 (11.8%) | 4 (23.5%) | 11 (64.7%) | |
Facial pain or pressure | 15 (88.2%) | 1 (5.9%) | 1 (5.9%) | |
Reduction or loss of smell | 12 (70.6%) | 0 | 4 (23.5%) | |
Allergic rhinitis | 17 | 7 (41%) | ||
Allergic Bronchopulmonary Aspergillosis (ABPA) | 17 | 2 (11.8%) | ||
History of nasal surgery | 17 | 6 (35%) | ||
Therapy | 17 | |||
Current azithromycin | 13 (77%) | |||
Current steroids nasal | 4 (24%) | |||
Recombinant DNase | 8 (47%) | |||
i.v. ABs (twice per day, mg/kg): | ||||
Ceftazidim (200)/tobramycin (10) | 11 (65%) | |||
Tobramycin (10)/meropenem (100) | 5 (29%) | |||
Ceftazidim (200)/tobramycin (10)/meropenem (100) | 1 (5.9%) | |||
Permanent colonisation LAW with*2: | 15 (88%) | |||
P. aeruginosa (mucoid) | 17 | 13 (76.5%) | ||
P. aeruginosa (non-mucoid) | 4 (23.5%) | |||
S. aureus | 7 (41%) | |||
Permanent/intermittent colonisation UAW with*3: | 7 (41.2%)/5 (29.4%) | |||
P. aeruginosa (mucoid) | 7 (41.2%) | |||
P. aeruginosa (non-mucoid) | 13 (76.5%) | |||
S. aureus | 3 (17.7%)/ 4 (23.5%) | |||
P. aeruginosa serum antibody positive: | 15 | |||
Alcaline protease | 3 (20%) | |||
Elastase | 6 (40%) | |||
Exotoxine A | 4 (27%) | |||